Assetmark, Inc Spring Works Therapeutics, Inc. Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 46,020 shares of SWTX stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,020

Previous 40,474 13.7%

Holding current value

$1.64 Million

Previous $1.52 Million 3.28%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$32.04 - $42.76 $177,693 - $237,146	5,546 Added 13.7%	46,020 $1.47 Million
Q2 2024 Aug 13, 2024	BUY	$36.06 - $47.62 $710,129 - $937,780	19,693 Added 94.76%	40,474 $1.52 Million
Q1 2024 May 06, 2024	BUY	$36.5 - $52.5 $171,221 - $246,277	4,691 Added 29.15%	20,781 $1.02 Million
Q4 2023 Feb 09, 2024	BUY	$18.94 - $37.24 $99,927 - $196,478	5,276 Added 48.79%	16,090 $587,000
Q3 2023 Oct 27, 2023	BUY	$23.12 - $31.38 $33,778 - $45,846	1,461 Added 15.62%	10,814 $250,000
Q2 2023 Aug 11, 2023	BUY	$23.15 - $32.71 $82,923 - $117,167	3,582 Added 62.07%	9,353 $245,000
Q1 2023 May 05, 2023	BUY	$24.97 - $34.05 $31,312 - $42,698	1,254 Added 27.76%	5,771 $148,000
Q4 2022 Feb 10, 2023	BUY	$21.73 - $28.72 $26,293 - $34,751	1,210 Added 36.59%	4,517 $117,000
Q3 2022 Nov 01, 2022	BUY	$24.1 - $39.66 $36,005 - $59,252	1,494 Added 82.4%	3,307 $94,000
Q2 2022 Aug 03, 2022	BUY	$18.36 - $60.07 $25,355 - $82,956	1,381 Added 319.68%	1,813 $45,000
Q1 2022 May 13, 2022	BUY	$48.97 - $65.46 $21,155 - $28,278	432 New	432 $24,000

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.22B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account